{"entity":{"id":"gamma-biotherapeutics","kind":"company","name":"Gamma Biotherapeutics","aka":["GAMMA BIOTHERAPEUTICS, INC."],"tldr":"Gamma Biotherapeutics is a Portland company whose antibody, M3T01, blocks Fas ligand, a molecule many tumours use to kill the T cells that attack them. It is in an early trial in people with advanced cancers.","summary":"Gamma Biotherapeutics, Inc., of Portland, Oregon, is a private clinical-stage company developing therapeutics that help the immune system fight cancer. Its lead programme M3T01 is a monoclonal antibody that neutralises Fas ligand, which many tumours produce and which triggers apoptosis in activated T cells; the company describes it as the first FasL-neutralising antibody to enter clinical trials. M3T01 is being tested alone and with pembrolizumab and other systemic therapies in a phase 1 trial in advanced solid tumours (NCT06719362), sponsored by Providence Health & Services. In fiscal year 2026 the National Cancer Institute funded its SBIR project on the clinical development of M3T01 for advanced cancers (1R44CA310416-01, USD 979,068).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.gammabiotherapeutics.com/"},{"label":"ClinicalTrials.gov: phase 1 trial of M3T01 (NCT06719362)","url":"https://clinicaltrials.gov/study/NCT06719362"},{"label":"NIH RePORTER: 1R44CA310416-01","url":"https://reporter.nih.gov/project-details/11315901"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["m3t01"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on gammabiotherapeutics.com, ClinicalTrials.gov (NCT06719362) and the NIH RePORTER record on 4 November 2026. The first-in-clinic statement is the company's own. No Fas ligand target record exists in the corpus."],"hq":"Portland, OR","country":"US","companyType":"biotech","website":"https://www.gammabiotherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":979068,"source":"https://reporter.nih.gov/project-details/11315901","note":"NCI SBIR (R44) award 1R44CA310416-01: Clinical development of the anti-fas ligand monoclonal antibody M3T01 for treatment of advanced cancers"}]},"route":"/companies/gamma-biotherapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"m3t01","kind":"drug","name":"M3T01","route":"/drugs/m3t01/"}]}}